New Zealand markets closed

Lyxor Stoxx Eurp 600 IndGd&Sv ETF AccA/I (INDP)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
2.2400-0.2500 (-10.04%)
At close: 04:00PM EDT
2.4700 +0.23 (+10.27%)
After hours: 05:28PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close2.4900
Open2.3900
Bid1.7300 x 200
Ask2.7500 x 200
Day's range2.0300 - 2.4200
52-week range1.5600 - 4.0800
Volume55,301
Avg. volume83,336
Market cap19.127M
Beta (5Y monthly)1.22
PE ratio (TTM)N/A
EPS (TTM)-1.8300
Earnings date03 May 2024 - 07 May 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est10.00
  • GlobeNewswire

    Indaptus Therapeutics to Present at the MedInvest Biotech and Pharma Investor Conference

    NEW YORK, March 28, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments, announces today that its CEO, Jeffrey Meckler will present a corporate overview at the MedInvest Biotech & Pharma Investor Conference. The conference is being held on April 3 - 4, 2024 at Cooley Law, 55 Hudson Yards, New York, NY 10001. Presentation Date: April 3, 2024Time: 9:55am ETWebcast Link:

  • GlobeNewswire

    Indaptus Therapeutics Previews Positive Mechanism of Action Data to be Presented at the American Association for Cancer Research Annual Meeting

    Data demonstrates that Company’s Decoy platform successfully induces or activates multiple immune cell types involved in anti-tumor responses New data shows activity in M1 macrophages, natural killer cells, dendritic cells, Th1 CD4, and CD8 T cells NEW YORK, March 25, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc, (Nasdaq: INDP), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments, announces that Dr. Michael Newman, Founder and Ch

  • GlobeNewswire

    Indaptus Therapeutics to Participate in Tribe Public Webinar On Wednesday, March 20, 2024

    Tribe Public Webinar with Indaptus Therapeutics Tribe Public Webinar with Indaptus Therapeutics “Fully Engaging The Human Immune System To Cure Disease,” Featuring CEO, Jeffrey MecklerRegistration now open at INDPMarch2024.TribePublic.com NEW YORK, March 18, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (NASDAQ: INDP), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments, announces that its CEO, Jeffrey Meckler, will present and p